Retatrutide

What it is

Retatrutide (development name LY3437943) is an investigational triple agonist — one molecule built to activate three receptors: GLP-1, GIP, and glucagon. It is the next conceptual step in a clear progression: semaglutide engaged one incretin pathway, tirzepatide engaged two, and retatrutide adds a third lever. It is the most-watched compound in the obesity pipeline — and, importantly, it is not approved.

How it is thought to work

The first two receptors do what they do in the other incretin drugs: improve insulin response, slow gastric emptying, and reduce appetite. The novel piece is the glucagon arm. Glucagon is best known for raising blood sugar — counterintuitive in a metabolic drug — but at the receptor level it is also associated with increased energy expenditure and effects on liver fat. The bet behind retatrutide is that pairing glucagon activity with the appetite-suppressing incretins lets the body burn more on top of eating less. That combination is the stated rationale for the unusually large weight changes seen early.

The evidence — striking, but unfinished

This is the part that generated headlines. In phase-2 work, the top-dose group reached roughly 24% average body-weight reduction at 48 weeks — the largest figure reported for an obesity drug at that stage, and notably the weight curve had not clearly plateaued, hinting the full effect might be larger still. That is genuinely remarkable. It is also, crucially, phase-2 — a mid-stage signal, not a finished verdict. Phase-3 trials are ongoing, and “striking phase-2 result” has never been the same thing as “approved drug with established long-term safety.”

The honest caveats

Side effects so far track the incretin class — predominantly gastrointestinal — but the added glucagon activity means the full safety and metabolic profile is still being characterized, which is exactly what the ongoing trials are for. And because nothing is approved, there is no legitimate supply: anything sold as “retatrutide” today is unapproved research-market material with no guarantee of identity, dose, or sterility, sold ahead of the evidence that would tell anyone whether it’s safe.

Where it stands

Retatrutide is the most exciting number in the field and the clearest illustration of the “add another receptor” trajectory. But it sits in the gap between promising and proven — and that gap is the whole story. The right way to read it is as the leading candidate to watch through phase 3, not as a finished product.